Literature DB >> 22085435

Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.

Yi-Dong Yan1, Jun Ho Sung, Kun Kook Kim, Dong Wuk Kim, Jong Oh Kim, Beom-Jin Lee, Chul Soon Yong, Han-Gon Choi.   

Abstract

With the aim of developing a novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes, various valsartan-loaded solid dispersions were prepared with water, hydroxypropyl methylcellulose (HPMC) and sodium lauryl sulphate (SLS). Effects of the weight ratios of SLS/HPMC and carrier/drug on both the aqueous solubility of valsartan and the drug-release profiles of solid dispersions were investigated. The physicochemical properties of solid dispersions were characterized using scanning electron microscope (SEM), differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The bioavailability of the solid dispersions in rats was evaluated compared to valsartan powder and a commercial product (Diovan). Unlike the conventional solid dispersion system, the valsartan-loaded solid dispersion had a relatively rough surface and did not change the crystalline form of the drug. It was suggested that the solid dispersions were formed by attaching hydrophilic carriers to the surface of the drug, thus changing from a hydrophobic to a hydrophilic form without changing the crystalline form. The drug-loaded solid dispersion composed of valsartan/HPMC/SLS at a weight ratio of 3/1.5/0.75 improved the drug solubility by about 43-fold. It gave a higher AUC, C(max) and shorter T(max) compared to valsartan powder and the commercial product. The solid dispersion improved the bioavailability of the drug in rats by about 2.2 and 1.7-fold in comparison with valsartan powder and the commercial product, respectively. Thus, the valsartan-loaded solid dispersion would be useful for delivering poorly water-soluble valsartan with enhanced bioavailability and no crystalline changes.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085435     DOI: 10.1016/j.ijpharm.2011.10.053

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  21 in total

1.  Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.

Authors:  Naveen Chella; Bhaskar Daravath; Dinesh Kumar; Rama Rao Tadikonda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

2.  Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers.

Authors:  Sarwar Beg; Suryakanta Swain; Harendra Pratap Singh; Ch Niranjan Patra; M E Bhanoji Rao
Journal:  AAPS PharmSciTech       Date:  2012-10-16       Impact factor: 3.246

3.  MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan.

Authors:  Wei Zhang; Tao Guo; Caifen Wang; Yuanzhi He; Xi Zhang; Guangyu Li; Yizhi Chen; Jun Li; Yangjing Lin; Xu Xu; Li Wu; Suxia Zhang; Jiwen Zhang
Journal:  Pharm Res       Date:  2019-06-03       Impact factor: 4.200

4.  Sustained release ivermectin-loaded solid lipid dispersion for subcutaneous delivery: in vitro and in vivo evaluation.

Authors:  Mengmeng Lu; Dan Xiong; Weiwei Sun; Tong Yu; Zixia Hu; Jiafeng Ding; Yunpeng Cai; Shizhuang Yang; Baoliang Pan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.

Authors:  Jae-Young Lee; Wie-Soo Kang; Jingpei Piao; In-Soo Yoon; Dae-Duk Kim; Hyun-Jong Cho
Journal:  Drug Des Devel Ther       Date:  2015-05-22       Impact factor: 4.162

6.  Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.

Authors:  Min-Soo Kim; In-Hwan Baek
Journal:  Int J Nanomedicine       Date:  2014-11-07

7.  Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization.

Authors:  Eun-Sol Ha; In-hwan Baek; Jin-Wook Yoo; Yunjin Jung; Min-Soo Kim
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

8.  Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels.

Authors:  Jyothi Sanaboina; K M Maheswari; Seetha Sunkara; Sravanthi Deekonda; Buchi N Nalluri
Journal:  J Pharm (Cairo)       Date:  2013-01-17

9.  Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe.

Authors:  Rehmana Rashid; Dong Wuk Kim; Abid Mehmood Yousaf; Omer Mustapha; Jong Hyuck Park; Chul Soon Yong; Yu-Kyoung Oh; Yu Seok Youn; Jong Oh Kim; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2015-09-30

10.  Control of Drug Dissolution Rate from Film Dosage Forms Containing Valsartan.

Authors:  Yoshifumi Murata; Kyoko Kofuji; Chieko Maida
Journal:  Int Sch Res Notices       Date:  2016-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.